Kangstem Biotech Obtains Domestic Patent for Large-Scale Cultivation Technology of Adult Stem Cells
[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 26th that it has obtained a domestic patent for its technology to develop high-performance adult stem cells, promoting proliferation, multipotency, and reprogramming.
This patent establishes standardized culture conditions through spherical growth that maintain an undifferentiated state, enabling the production of adult stem cells with CD49f-positive characteristics that promote stem cell proliferation, multipotency, and reprogramming without undergoing costly steps in the process.
Hot Picks Today
"Why Live in Seoul When You Can Pay Half Here?" 30 Minutes to Gangnam... Private Sales Begin in Gyeyang New Town
- "Living Becomes Easier Thanks to SK Hynix, But Conservative U.S. Cities Remain Torn Inside [U.S. Midterm Election D-40]②-2"
- "I Went for the Cheap Coffee, but Now I Feel Uneasy"... Major Coffee Franchises Cited for Violations One After Another
- "Had All My Tickets Booked for Chuseok"... Measles Outbreak and Typhoon Cause Chaos, but Japan Remains Top Choice
- "After Spending 170,000 Won on Hanwoo, This Is What I Got": Why Webtoon Artist Kim Gyusam Decided to Give Cash Instead
The company stated, "Based on this, we will be able to manufacture highly efficient stem cell therapeutics," adding, "It can also be used for the treatment of immune-related diseases as well as neurological, cardiovascular, and skeletal system disorders."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
